Summary
Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know
Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for July 22nd
HTLD, YEXT, ANIX, WVE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 2026.
Here's Why You Should Add ANIX Stock to Your Portfolio Now
Anixa advances cancer vaccines and CAR-T therapies, supported by positive early data, a planned phase II study and expanding intellectual property protection.
Anixa Biosciences Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 17,276 | $53,901.28 | $59,774.96 | $5,873.68 | 10.9% |
 Kyle P. Smith NewEdge Wealth LLC | 12,500 | $41,250 | $43,437.5 | $2,187.5 | 5.3% |
 Rekah Franca Catalyst Funds Management Pty Ltd. | 12,300 | $31,734 | $43,480.5 | $11,746.5 | 37.02% |
| CAL CoreCap Advisors LLC CoreCap Advisors LLC | 52,020 | $158,144.5 | $179,989.2 | $21,844.7 | 13.81% |
 Marc H. Stone Tyler-Stone Wealth Management | 42,016 | $128,568.96 | $145,547.63 | $16,978.67 | 13.21% |
Anixa Biosciences Inc. (ANIX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Anixa Biosciences Inc. ever had a stock split?
Anixa Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Amit Kumar CEO | NASDAQ (CM) Exchange | 03528H109 CUSIP |
| US Country | 4 Employees | - Last Dividend | 26 Jun 2015 Last Split | 1 Jan 1987 IPO Date |
Overview
Anixa Biosciences, Inc. is a pioneering biotechnology enterprise committed to the innovation of novel treatments and vaccines addressing the urgent needs within oncology and infectious diseases sectors. Since its inception in 1982 and formerly known as ITUS Corporation before rebranding in October 2018, Anixa has been at the forefront of developing groundbreaking therapies. Headquartered in San Jose, California, the company concentrates on leveraging advancements in science and technology to create solutions for diseases with significant unmet medical needs, particularly focusing on various forms of cancer.
Products and Services
- Chimeric Endocrine Receptor T-Cell Therapy
This novel form of chimeric antigen receptor T-cell (CAR-T) technology is under development by Anixa Biosciences with a primary focus on treating ovarian cancer. By tailoring the body's own immune cells to better recognize and fight cancer, this therapy represents a promising advance in personalized medicine for ovarian cancer patients.
- Vaccine Against Triple Negative Breast Cancer
An innovative project undertaken by Anixa is the development of a vaccine aimed at combating triple negative breast cancer. This form of breast cancer is particularly challenging to treat due to the lack of hormone receptors, which are typically targeted in other breast cancer treatments. Anixa's vaccine seeks to stimulate the immune system to prevent or treat this aggressive type of cancer.
- Preventative Vaccine Against Ovarian Cancer
Focusing on prevention, Anixa is also working on a vaccine aimed at ovarian cancer, one of the most deadly forms of gynecological cancer. The goal of this vaccine is to train the immune system to recognize and eliminate cells that could potentially develop into cancer, thus offering a prophylactic solution to high-risk individuals.
- Immuno-Therapy Drugs Against Cancer
Aside from vaccines and targeted cell therapies, Anixa Biosciences is also developing a range of immuno-therapy drugs designed to empower the immune system in fighting against cancer. These drugs work by various mechanisms to enhance the body's natural defense systems, showing promise in treating different types of cancer.
